Biohaven Pharmaceuticals has started late-stage human testing on a new pill for migraine prevention, a milestone that entitles the company to a $100 million payout under a 2020 deal with Royalty Pharma.
Biohaven said it would use the Royalty Pharma cash to advance Biohaven’s zavegepant for migraine and explore its use for other pain-related and non-migraine conditions.